Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BGNE

BeiGene (BGNE) Stock Price, News & Analysis

BeiGene logo

About BeiGene Stock (NASDAQ:BGNE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$174.72
$217.22
52-Week Range
N/A
Volume
331,608 shs
Average Volume
337,614 shs
Market Capitalization
$18.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$253.92
Consensus Rating
Moderate Buy

Company Overview

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
See More Headlines

BGNE Stock Analysis - Frequently Asked Questions

BeiGene, Ltd. (NASDAQ:BGNE) announced its earnings results on Tuesday, November, 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by $0.04. The firm's quarterly revenue was up 28.2% on a year-over-year basis.

BeiGene (BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that BeiGene investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Saia (SAIA).

Company Calendar

Last Earnings
11/12/2024
Today
7/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BGNE
CIK
1651308
Fax
N/A
Employees
9,000
Year Founded
2010

Price Target and Rating

High Price Target
$300.00
Low Price Target
$152.50
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$881.71 million
Pretax Margin
-24.07%

Debt

Sales & Book Value

Annual Sales
$3.32 billion
Price / Cash Flow
N/A
Book Value
$37.10 per share
Price / Book
N/A

Miscellaneous

Free Float
90,195,000
Market Cap
$18.03 billion
Optionable
Optionable
Beta
0.57

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:BGNE) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners